What is Leerink Partnrs’ Forecast for STOK Q1 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman expects that the company will post earnings per share of ($0.49) for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.79) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($3.00) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at $0.55 EPS.

STOK has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. Chardan Capital reiterated a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $8.15 on Friday. The firm has a market capitalization of $431.68 million, a price-to-earnings ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 1 year low of $5.93 and a 1 year high of $17.58. The business has a 50 day simple moving average of $9.47 and a 200-day simple moving average of $11.45.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP lifted its position in Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after acquiring an additional 471,240 shares during the period. Baker BROS. Advisors LP raised its stake in shares of Stoke Therapeutics by 6.1% during the 4th quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after buying an additional 265,395 shares during the last quarter. Toronto Dominion Bank purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $35,001,000. State Street Corp raised its stake in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after buying an additional 137,145 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in shares of Stoke Therapeutics by 2.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after buying an additional 38,446 shares during the last quarter.

Insider Activity

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 16,532 shares of company stock worth $143,332. 11.30% of the stock is currently owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.